Lauren A King1, Nicolas Wentzensen2, Mark P Purdue2, Hormuzd A Katki2, Ligia A Pinto3, Britton Trabert2. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; University of Virginia School of Medicine, Department of Obstetrics and Gynecology, Charlottesville, VA. Electronic address: lak9um@virginia.edu. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 3. Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Abstract
BACKGROUND: Associations between benign gynecologic pathologies and circulating inflammatory markers are unknown. Our goal was to evaluate self-reported history of benign gynecologic pathology and subsequent alterations in systemic inflammation. METHODS: Using nested case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, study-specific associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations were evaluated using logistic regression and combined using meta-analysis. Inflammatory markers associated with individual benign pathologies were mutually adjusted for one another to evaluate independent associations. RESULTS: Compared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (OR [95% CI] 6.24 [2.53-15.39], P <.001) and TGF-β1 (3.79 [1.62-8.86], P =.002) and decreased BCA-1 (0.38 [0.19-0.73], P =.004). Uterine fibroids were associated with decreased CXCL11 (0.37 [0.22-0.63], P <.001) and VEGFR3 (0.40 [0.24-0.65], P <.001). Endometriosis was associated with increased SIL-4R (4.75 [1.84-12.26], P =.001). CONCLUSIONS: Self-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life.
BACKGROUND: Associations between benign gynecologic pathologies and circulating inflammatory markers are unknown. Our goal was to evaluate self-reported history of benign gynecologic pathology and subsequent alterations in systemic inflammation. METHODS: Using nested case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, study-specific associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations were evaluated using logistic regression and combined using meta-analysis. Inflammatory markers associated with individual benign pathologies were mutually adjusted for one another to evaluate independent associations. RESULTS: Compared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (OR [95% CI] 6.24 [2.53-15.39], P <.001) and TGF-β1 (3.79 [1.62-8.86], P =.002) and decreased BCA-1 (0.38 [0.19-0.73], P =.004). Uterine fibroids were associated with decreased CXCL11 (0.37 [0.22-0.63], P <.001) and VEGFR3 (0.40 [0.24-0.65], P <.001). Endometriosis was associated with increased SIL-4R (4.75 [1.84-12.26], P =.001). CONCLUSIONS: Self-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life.
Authors: Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2014-08-23 Impact factor: 5.482
Authors: Jacqueline V Aredo; Katrina J Heyrana; Barbara I Karp; Jay P Shah; Pamela Stratton Journal: Semin Reprod Med Date: 2017-01-03 Impact factor: 1.303
Authors: Anil K Chaturvedi; Troy J Kemp; Ruth M Pfeiffer; Angelique Biancotto; Marcus Williams; Stella Munuo; Mark P Purdue; Ann W Hsing; Ligia Pinto; J Philip McCoy; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-29 Impact factor: 4.254
Authors: Richard B Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen-Yi Huang; Paul Pinsky; Douglas Reding; Edward P Gelmann; Nat Rothman; Ruth M Pfeiffer; Robert N Hoover; Christine D Berg Journal: Mutat Res Date: 2005-07-27 Impact factor: 2.433
Authors: Mark P Purdue; Jonathan N Hofmann; Troy J Kemp; Anil K Chaturvedi; Qing Lan; Ju-Hyun Park; Ruth M Pfeiffer; Allan Hildesheim; Ligia A Pinto; Nathaniel Rothman Journal: Blood Date: 2013-06-27 Impact factor: 22.113
Authors: Claire Heit; Brian C Jackson; Monica McAndrews; Mathew W Wright; David C Thompson; Gary A Silverman; Daniel W Nebert; Vasilis Vasiliou Journal: Hum Genomics Date: 2013-10-30 Impact factor: 4.639
Authors: Nilufer Rahmioglu; Dale R Nyholt; Andrew P Morris; Stacey A Missmer; Grant W Montgomery; Krina T Zondervan Journal: Hum Reprod Update Date: 2014-03-27 Impact factor: 15.610